Strategic Investment Advisors MI Decreases Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Strategic Investment Advisors MI lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILDFree Report) by 81.9% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 10,443 shares of the biopharmaceutical company’s stock after selling 47,213 shares during the period. Strategic Investment Advisors MI’s holdings in Gilead Sciences were worth $965,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. State Street Corp increased its holdings in Gilead Sciences by 1.4% during the third quarter. State Street Corp now owns 60,171,691 shares of the biopharmaceutical company’s stock worth $5,044,795,000 after buying an additional 841,776 shares during the last quarter. Wellington Management Group LLP increased its stake in shares of Gilead Sciences by 50.9% in the third quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock worth $2,900,921,000 after purchasing an additional 11,665,593 shares in the last quarter. FMR LLC increased its stake in shares of Gilead Sciences by 79.4% in the third quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock worth $2,780,329,000 after purchasing an additional 14,680,161 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Gilead Sciences by 2.1% in the third quarter. Geode Capital Management LLC now owns 27,540,870 shares of the biopharmaceutical company’s stock worth $2,302,119,000 after purchasing an additional 574,421 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Gilead Sciences by 3.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 7,752,975 shares of the biopharmaceutical company’s stock worth $650,009,000 after purchasing an additional 224,960 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

NASDAQ GILD opened at $93.07 on Monday. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $98.90. The firm has a market capitalization of $115.99 billion, a P/E ratio of 1,034.11, a PEG ratio of 1.31 and a beta of 0.18. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The company has a 50-day moving average price of $91.74 and a 200-day moving average price of $84.98.

Gilead Sciences (NASDAQ:GILDGet Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. During the same period last year, the firm posted $2.29 EPS. The company’s revenue was up 7.0% on a year-over-year basis. Equities research analysts anticipate that Gilead Sciences, Inc. will post 4.36 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were paid a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 3.31%. The ex-dividend date was Friday, December 13th. Gilead Sciences’s payout ratio is 3,422.22%.

Insiders Place Their Bets

In other Gilead Sciences news, insider Merdad Parsey sold 25,590 shares of the business’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total value of $2,341,485.00. Following the completion of the transaction, the insider now directly owns 99,599 shares in the company, valued at approximately $9,113,308.50. The trade was a 20.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the transaction, the chief financial officer now owns 129,873 shares of the company’s stock, valued at $11,863,898.55. This represents a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 456,234 shares of company stock valued at $42,130,461 over the last three months. 0.16% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

GILD has been the subject of several recent research reports. BMO Capital Markets lifted their target price on shares of Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Thursday, November 7th. Daiwa America upgraded shares of Gilead Sciences to a “hold” rating in a research note on Monday, November 18th. Barclays raised their price objective on shares of Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a research report on Thursday, November 7th. Finally, Oppenheimer raised their price objective on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. Eleven analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $97.96.

View Our Latest Research Report on GILD

Gilead Sciences Profile

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

See Also

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILDFree Report).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.